Scalper1 News
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making investments to get part of NASH, a form of liver damage caused by accumulation of fat. Regulus said RG-125, a compound to treat nonalcoholic steatohepatitis (NASH) in patients with type II diabetes or Scalper1 News
Scalper1 News